300753.SHE Jiangsu Apon Medical Technology Co Ltd Class A
- Market cap
- CNY 2.44B
- P/E
- -
- P/B
- 3.99x
- ROE
- -3.4%
- Dividend yield
- 0.42%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300753.SHE undervalued?
Graham numberThe Graham number of Jiangsu Apon Medical Technology Co Ltd Class A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Apon Medical Technology Co Ltd Class A fundamental analysis
No fundamental analysis for Jiangsu Apon Medical Technology Co Ltd Class A yet.
Jiangsu Apon Medical Technology Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Apon Medical Technology Co Ltd Class A
Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices for anesthesia and analgesia, nasal airway, and chronic pain management in China. It offers pain management services, such as high-precision intelligent microcomputer infusion pumps, wireless analgesia management systems, internal heat needle therapy devices, low-frequency therapy devices, and shockwave therapy devices; and iPainfree, a wireless analgesi…
Full company profileJiangsu Apon Medical Technology Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Apon Medical Technology Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 198M | 247M | 298M | 380M | 443M | 461M | 324M | 422M | 404M | 342M | 309M |
| Gross Profit | 147M | 185M | 228M | 268M | 254M | 295M | 160M | 276M | 276M | 234M | 202M |
| Operating Income | 49.1M | 70.7M | 85.6M | 121M | 114M | 55.8M | -88.3M | 14.0M | 23.5M | -25.9M | -30.5M |
| EBITDA | 64.0M | 78.8M | 93.1M | 128M | 122M | 69.3M | -74.5M | 29.5M | 38.5M | -1.43M | -33.4M |
| Net Income | 47.7M | 57.9M | 70.1M | 102M | 97.0M | 54.1M | -76.0M | 8.28M | 10.8M | -24.0M | -22.3M |
| EPS | 0.51 | 0.62 | 0.74 | 0.81 | 0.77 | 0.43 | -0.60 | 0.07 | 0.09 | -0.19 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 295M | 333M | 688M | 758M | 827M | 899M | 870M | 860M | 863M | 860M | 836M |
| Total Liabilities | 64.9M | 53.9M | 74.6M | 82.8M | 87.4M | 119M | 184M | 162M | 156M | 180M | 175M |
| Shareholders' Equity | 224M | 272M | 605M | 675M | 740M | 780M | 686M | 696M | 700M | 667M | 651M |
| Cash & Short-term Investments | 142M | 170M | 436M | 421M | 389M | 275M | 249M | 202M | 203M | 165M | 81.2M |
| Total Debt | - | - | - | - | 3.73M | 39.9M | 68.4M | 76.4M | 76.7M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 61.0M | 67.1M | 78.1M | 77.6M | 83.3M | 18.3M | -24.6M | -23.3M | 15.7M | 2.33M | - |
| Capital Expenditure | 4.33M | 15.7M | 61.6M | 58.3M | 35.6M | 39.6M | 24.2M | 30.7M | 10.2M | 8.43M | 5.17M |
| Free Cash Flow | 56.6M | 51.4M | 16.5M | 19.3M | 47.7M | -21.3M | -48.8M | -54.1M | 5.45M | -6.10M | -12.6M |
| Ratios | |||||||||||
| ROE | 21.3% | 21.3% | 11.6% | 15.2% | 13.1% | 6.9% | -11.1% | 1.2% | 1.5% | -3.6% | -3.4% |
| ROA | 16.2% | 17.4% | 10.2% | 13.5% | 11.7% | 6.0% | -8.7% | 1.0% | 1.3% | -2.8% | -2.7% |
| Net Profit Margin | 24.1% | 23.5% | 23.5% | 27.0% | 21.9% | 11.7% | -23.5% | 2.0% | 2.7% | -7.0% | -7.2% |
| Debt to Equity | - | - | - | - | 0.01x | 0.05x | 0.10x | 0.11x | 0.11x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Apon Medical Technology Co Ltd Class A dividends
- Dividend yield
- 0.42%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 10.1M | 0.08 | - |
| 2024 | CNY 9.65M | 0.08 | 89.3% |
| 2023 | CNY 1.33M | 0.01 | 16.0% |
| 2022 | CNY 634K | 0.01 | - |
| 2021 | CNY 31.5M | 0.25 | 58.3% |
| 2020 | CNY 32.3M | 0.26 | 33.3% |
| 2019 | CNY 32.3M | 0.26 | 31.6% |
| 2018 | CNY 32.3M | 0.34 | 46.1% |
| 2017 | CNY 10.0M | 0.11 | 17.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 2, 2021.
Who owns Jiangsu Apon Medical Technology Co Ltd Class A
- Insiders 41.39%
- Institutions 3.33%
- Public & others 55.28%
- Shares outstanding 126M
- Free float 75.4M
Jiangsu Apon Medical Technology Co Ltd Class A company profile
- Company name
- Jiangsu Apon Medical Technology Co Ltd Class A
- Ticker
- 300753.SHE
- ISIN
- CNE100003FV4
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 592
- Fiscal year end
- December
- Address
- East Side of Yongtong Avenue, Nantong, China
- Phone
- 86 51 3801 58833
- Website
- apon.com.cn
About Jiangsu Apon Medical Technology Co Ltd Class A
Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices for anesthesia and analgesia, nasal airway, and chronic pain management in China. It offers pain management services, such as high-precision intelligent microcomputer infusion pumps, wireless analgesia management systems, internal heat needle therapy devices, low-frequency therapy devices, and shockwave therapy devices; and iPainfree, a wireless analgesia management system software. The company also provides nasal and upper airway management solutions, including daily nasal care, perioperative care for nasal diseases, rhinitis diagnosis and treatment, snoring diagnosis and treatment, and allergy treatment; and sleep monitoring and improvement solutions. In addition, it is involved in research and development of digital diagnostic and treatment products for neurological diseases, cognitive training, and sleep monitoring; and research, development, production, and sale of medical devices comprising brain neuromodulation and intracranial implantable electrodes. Jiangsu Apon Medical Technology Co., Ltd. was founded in 2001 and is headquartered in Nantong, China.
Jiangsu Apon Medical Technology Co Ltd Class A management
5- Mr. Zhi Hui ZhangGM & Director · born 1971
- Mr. Dongqi YuanDeputy GM & CFO · born 1977
- Mr. Yu Fei YeSecretary to the Board · born 1987
- Mr. Haifeng YingDeputy General Manager · born 1976
- Yanfei ShiAccounting Supervisor